2024-11-01 2025-10-31 false Capium Accounts Production 1.1 16043198 2024-11-01 2025-10-31 16043198 bus:FullAccounts 2024-11-01 2025-10-31 16043198 bus:FRS102 2024-11-01 2025-10-31 16043198 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 16043198 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 16043198 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 16043198 2024-11-01 2025-10-31 16043198 2025-10-31 16043198 bus:RegisteredOffice 2024-11-01 2025-10-31 16043198 core:WithinOneYear 2025-10-31 16043198 core:AfterOneYear 2025-10-31 16043198 1 2024-11-01 2025-10-31 16043198 bus:Director1 2024-11-01 2025-10-31 16043198 bus:Director1 2025-10-31 16043198 2023-11-01 16043198 bus:LeadAgentIfApplicable 2024-11-01 2025-10-31 16043198 2024-10-31 16043198 core:ComputerEquipment 2024-11-01 2025-10-31 16043198 core:ComputerEquipment 2025-10-31 16043198 core:ComputerEquipment 2024-10-31 16043198 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-10-31 16043198 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-10-31 16043198 core:CostValuation core:Non-currentFinancialInstruments 2025-10-31 16043198 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 16043198 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-10-31 16043198 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16043198 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16043198 core:Non-currentFinancialInstruments 2025-10-31 16043198 core:Non-currentFinancialInstruments 2024-10-31 16043198 core:ShareCapital 2025-10-31 16043198 core:RetainedEarningsAccumulatedLosses 2025-10-31 16043198 core:ShareCapitalOrdinaryShares 2024-11-01 16043198 core:ShareCapitalOrdinaryShares 2024-11-01 2025-10-31 16043198 core:ShareCapitalOrdinaryShares 2025-10-31 16043198 core:RevaluationReserve 2024-11-01 16043198 core:RevaluationReserve 2024-11-01 2025-10-31 16043198 core:RevaluationReserve 2025-10-31 16043198 core:CapitalRedemptionReserve 2024-11-01 16043198 core:CapitalRedemptionReserve 2024-11-01 2025-10-31 16043198 core:CapitalRedemptionReserve 2025-10-31 16043198 core:RetainedEarningsAccumulatedLosses 2024-11-01 16043198 core:RetainedEarningsAccumulatedLosses 2024-11-01 2025-10-31 16043198 core:RetainedEarningsAccumulatedLosses 2025-10-31 16043198 dpl:Item1 2024-11-01 16043198 dpl:Item1 2025-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 16043198
England and Wales

 

 

 

MEDFLEX LOCUM LTD



Unaudited Financial Statements
 


Period of accounts

Start date: 01 November 2024

End date: 31 October 2025

MEDFLEX LOCUM LTD
Contents Page
For the year ended 31 October 2025
Director Mohamed Abdelbasat Abdelaziz Elbasty
Registered Number 16043198
Registered Office 36 Leamington
Great Sanky
Warrington
WA5 3PY
Accountants JAS ACCOUNTANCY SERVICES
32 Royton Avenue
Sale
M33 2TX
1
Director's report and financial statements
The director presents his/her/their annual report and the financial statements for the year ended 31 October 2025.
Principal activities
Principal activity of the company during the financial  year ended 31 October 2025  was of general medical practice activities.
Director
The director who served the company throughout the year was as follows:
Mohamed Abdelbasat Abdelaziz Elbasty
Statement of director's responsibilities
The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.

In preparing these financial statements, the director is required to :
  • select suitable accounting policies and then apply them consistently
  • make judgements and accounting estimates that are reasonable and prudent
  • state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and
  • prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions

On behalf of the board.


----------------------------------
Mohamed Abdelbasat Abdelaziz Elbasty
Director

Date approved: 20 July 2026
2
Report to the directors on the preparation of the unaudited statutory accounts of MEDFLEX LOCUM LTD for the year ended 31 October 2025
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of MEDFLEX LOCUM LTD for the year ended 31 October 2025 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given to us.

As a practising member firm of the Institute of Financial Accountants (IFA), we are subject to its ethical and other professional requirements which are detailed at https://www.ifa.org.uk/about-us/acting-in-the-public-interest/memberregulations.

This report is made solely to the Board of Directors of MEDFLEX LOCUM LTD, as a body, in accordance with the terms of our engagement letter dated 20 July 2026. Our work has been undertaken solely to prepare for your approval the accounts of MEDFLEX LOCUM LTD and state those matters that we have agreed to state to the Board of Directors of MEDFLEX LOCUM LTD, as a body, in this report.To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than MEDFLEX LOCUM LTD and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that MEDFLEX LOCUM LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit or loss of MEDFLEX LOCUM LTD.You consider that MEDFLEX LOCUM LTD is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit of the accounts of MEDFLEX LOCUM LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements 31 October 2025.



....................................................

JAS ACCOUNTANCY SERVICES
32 Royton Avenue
Sale
M33 2TX
20 July 2026
3
 
 		 Notes
 		 2025
£
Turnover 54,503 
Gross profit 54,503 
Administrative expenses (26,085)
Other operating income 22 
Operating profit 28,440 
Profit/(Loss) on ordinary activities before taxation 28,440 
Tax on profit on ordinary activities (5,300)
Profit/(Loss) for the financial year 23,140 
 
4
 
 		 Notes
 		 2025
£
Fixed assets    
Tangible fixed assets 3 544 
544 
Current assets    
Cash at bank and in hand 14,333 
Creditors: amount falling due within one year 4 (8,145)
Net current assets 6,188 
 
Total assets less current liabilities 6,732 
Net assets 6,732 
 

Capital and reserves 		   
Called up share capital 2 
Profit and loss account 6,730 
Shareholders' funds 6,732 
 


For the year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 20 July 2026 and were signed by:


-------------------------------
Mohamed Abdelbasat Abdelaziz Elbasty
Director
5
  Equity share capital   Revaluation reserve   Capital redemption reserve   Retained Earnings   Total
£ £ £ £ £
At 01 November 2024 - 
Profit/(Loss) for the year 23,140  23,140 
Total comprehensive income for the year -  -  -  23,140  23,140 
Dividends (16,410) (16,410)
Shares issued 2  2 
Total investments by and distributions to owners 2  -  -  (16,410) (16,408)
At 31 October 2025 2  6,730  6,732 
6
General Information
MEDFLEX LOCUM LTD is a private company, limited by shares, registered in England and Wales, registration number 16043198, registration address 36 Leamington , Great Sanky, Warrington, WA5 3PY.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 20% Reducing Balance
2.

Average number of employees

Average number of employees during the year was 1.
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 November 2024 -    - 
Additions 680    680 
Disposals -    - 
At 31 October 2025 680    680 
Depreciation
At 01 November 2024 -    - 
Charge for year 136    136 
On disposals -    - 
At 31 October 2025 136    136 
Net book values
Closing balance as at 31 October 2025 544    544 
Opening balance as at 01 November 2024 -    - 


4.

Creditors: amount falling due within one year

2025
£
Corporation Tax 5,300 
Directors' Current Accounts 2,845 
8,145 

7